Autolus Therapeutics Reports First Quarter 2024 Financial Re

Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHATwo patients enrolled in Phase 1 Systemic Lupus Erythematosus trial;...

Related Keywords

United Kingdom , United States , London , City Of , Stevenage , Hertfordshire , American , Julia Wilson , June Dec , Susana Noonan , Olivia Manser , Ravi Rao , Johnh Johnson , European Medicines Agency , University College London , European Hematology Association , Cardinal Health , Nature Communications , Sa Noonan Communications , American Society Of Clinical Oncology , Nasdaq , Exchange Commission , Ferrari , Lupus Erythematosus , Authorization Application , Christian Itin , Chief Executive Officer , Systemic Lupus Erythematosus , B Cell Acute Lymphoblastic Leukemia , Biologics License Application , American Society , Clinical Oncology , Multiple Myeloma , Importation Authorization , Marketing Authorization Application , Mike Bonney , Non Executive Director , Structure Guided Engineering , Nat Commun , Blood Cancer Journal , Dualt Cell , Blood Cancer , News Flow , Quarter Ended March , Unaudited Condensed Consolidated Statements , Comprehensive Loss , Months Ended March , Autolus Therapeutics , Private Securities Litigation Reform Act , Autolu Annual Report ,